NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

NCT01900431

CompletedPhase 2

Sponsor: Sanofi

Conditions: Uveitis

Interventions: Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab)

Countries: United States, Czechia, France, Italy, Spain, Turkey (Türkiye)

Primary Objective: To evaluate the efficacy of sarilumab at Week 16 in participants with non-infectious uveitis (NIU). Secondary Objectives: To evaluate the change in best corrected visual acuity (BCVA). To evaluate the safety of subcutaneous sarilumab in participants with NIU. To evaluate the change in macular edema. To evaluate the change in other signs of ocular inflammation. To evaluate the effect on retinal vessel leakage. To evaluate the effect of sarilumab on reducing concomitant immunosuppressant therapy. To evaluate the change in ocular inflammation in the anterior chamber. To evaluate the pharmacokinetics of sarilumab in NIU participants. To evaluate the immunogenicity with anti-drug antibodies (ADA).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion criteria:

* ≥18 years of age.
* Non-infectious intermediate, posterior, or pan-uveitis in the study eye.
* Active disease at screening or evidence of activity within the 3 months prior to screening visit. Following the approval of amendment-2, only participants with "active disease" as defined above were enrolled in the study.
* Starting oral prednisone dose must be greater than or equal to 15 mg/day and less than 80 mg/day.
* At screening, participants must be receiving oral prednisone (≥15 mg and \<80 mg/day \[or equivalent oral corticosteroid\]) as single immunosuppressive therapy or in combination with MTX (≤25 mg/week) orally or intravenously or intramuscular or subcutaneous). -
* Participants could be receiving one or several of the following therapies: Azathioprine (≤2.5 mg/kg/day), Mycophenolate mofetil (≤2 g daily, orally), Cyclosporine (≤4 mg/kg daily, orally), Tacrolimus (≤4 mg daily, orally).
* The doses might not had been increased for at least 4 weeks prior to the randomization visit.
* At randomization, participants had been receiving oral prednisone (≥15 mg and \<80 mg/day \[or equivalent oral corticosteroid\]) as single immunosuppressive therapy or in combination with MTX (≤25 mg/week) orally or intravenously or intramuscular or subcutaneous).
* Azathioprine, mycophenolate mofetil, cyclosporine and tacrolimus had to be permanently discontinued at least 48 hours prior to the first study treatment injection, or longer as per Investigator's judgment. These immunomodulatory therapies (IMTs) were not permitted anytime during the treatment period.
* Signed written informed consent.

Exclusion criteria:

* Participants with best-corrected visual acuity (BCVA) worse than 20 early treatment diabetic retinopathy study (ETDRS) letters in at least one eye.
* Participants with confirmed or suspected uveitis of infectious etiology or uveitis of traumatic etiology.
* Participants with primary diagnosis of anterior uveitis.
* Prior treatment with anti-interleukin-6 (IL-6) or interleukin-6 receptor complex (IL-6R) antagonist therapies, including tocilizumab and sarilumab.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Locations (20)

Worcester, Massachusetts, United States
Omaha, Nebraska, United States
Slingerlands, New York, United States
Cleveland, Ohio, United States
Arlington, Texas, United States
Brno, Czechia
Prague, Czechia
Paris, France
Paris, France
Milan, Italy
Padova, Italy
Reggio Emilia, Italy
Barcelona, Spain
Barcelona, Spain
Ankara, Turkey (Türkiye)
Ankara, Turkey (Türkiye)
Istanbul, Turkey (Türkiye)
Istanbul, Turkey (Türkiye)
Izmir, Turkey (Türkiye)
Izmir, Turkey (Türkiye)